$IVA

Novo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.

Inventiva (IVA) will present five abstracts at the 12th Paris MASH Meeting, showcasing Phase 1 and 2 clinical and preclinical data for lanifibranor, its lead drug candidate. The data suggests improvements in metabolic profiles and cardiovascular risk factors in MASH patients, with or without type 2 diabetes. Lanifibranor is currently in a Phase 3 trial, with topline results expected in Q4 2026.

Inventiva (Euronext: IVA, NASDAQ: IVA) appointed Chris Benecchi as Chief Operating Officer to lead operational readiness ahead of its Phase 3 trial results for lanifibranor, a potential MASH treatment, expected in Q4 2026. Benecchi brings extensive biopharmaceutical experience and will prepare the company for a potential 2028 U.S. launch, subject to regulatory approval.

Inventiva (Euronext Paris and Nasdaq: IVA) reported preliminary 1H 2026 results. Cash and cash equivalents were €166.1 million at June 30, 2026, versus €99.3 million at Dec. 31, 2025. Net cash used in operating activities was (€48.7) million. R&D expenses were (€50.1) million. No revenues were recorded. The company expects funding into Q2 2027, or Q1 2028 with potential tranches.

Inventiva S.A. (NASDAQ:IVA) said July 9 it completed the final step of its June 2, 2026 EIB warrant restructuring. The company issued about 15.7 million new warrants to the European Investment Bank and canceled remaining legacy EIB warrants not repurchased. Inventiva said the change removes anti-dilution provisions and improves capital structure as it advances lanifibranor for MASH.

Inventiva (Euronext Paris and Nasdaq: IVA) said it completed its EIB warrant restructuring, issuing 15.7 million new EIB warrants to the European Investment Bank and cancelling remaining legacy EIB warrants not repurchased. New warrants are priced and exercisable at €0.01, expire Jan. 4, 2036, and would equal about 6.5% of current share capital if exercised.

Inventiva (Euronext Paris/Nasdaq: IVA) reported voting results from its Combined Shareholders’ General Meeting on June 30, 2026. Shareholders adopted all resolutions except the 31st, which would have authorized share capital increases for a company savings plan. The meeting also approved the 2025 compensation policy for corporate officers. Total shares with voting rights: 236,280,202; quorum: 71.874%.

Gide advised Inventiva, a biopharmaceutical company, on combined cross-border financing. According to Gide, Inventiva raised about $120m via an offering of American depositary shares in the U.S., and arranged new bond and convertible bond financing of €75m initially (up to €130m subject to conditions). The transactions also included a €50m repurchase of EIB warrants and full repayment of existing EIB debt. Cooley advised on U.S. law.

Claret Capital Partners will invest €43m in Inventiva (Euronext Paris and Nasdaq: IVA) as part of Inventiva’s €130m committed debt financing, with an additional uncommitted tranche of up to €20m, according to the companies. The funding supports Phase 3 development of lanifibranor for MASH; Inventiva expects NATiV3 top-line readout in Q4 2026.

Inventiva said it completed key steps of a combined EIB and new debt financing transaction on June 12, 2026. It prepaid EIB loans of about €62.2m and repurchased/cancelled EIB warrants for €50m (including 700,000 Tranche B warrants). It issued Tranche A convertible bonds (€35m) and Tranche B amortized bonds (€40m) for €71.3m net proceeds, with conversion price €5.2893 and lender warrant exercise price €4.1559.